Branded ashwagandha and curcumin complex may offer allergy relief according to recent study

Photo © iStockphoto.com/Matt_Brown

Akay Bioactives announced the publication of a randomized placebo-controlled study¹ investigating the effects of its Immufen ingredient on mild allergic rhinitis. Immufen is a complex of ashwagandha and curcumin standardized to withanolides and curcuminoids using the company’s FenuMat technology. According to Akay, FenuMat is a plant-based co-delivery system that ensures consistent release of soluble bioactives to optimized overall bioavailability.

In the 28-day study, 105 participants were randomized to receive either the ashwagandha and curcumin complex, a bioavailable curcumin, or placebo twice daily. Researchers measured allergic rhinitis symptoms and quality of life using Total Nasal Symptom Score (TNSS), Bergen Insomnia Scale (BIS), and the Profile of Mood States Short Form (POMS-SF) questionnaire at both baseline and study completion.

Results showed the complex significantly decreased symptoms associated with allergic rhinitis. Specifically, the complex reduced nasal congestion by 34.64%, runny rose by 33.01%, nasal itching by 29.77%, sneezing by 32.76%, and TNSS by 31.62%. Compared to the complex, the bioavailable curcumin did not significantly effect symptoms and TNSS, except sneezing.

"These results represent a significant breakthrough in natural, plant-based solutions for seasonal health,” said Krishnakumar IM, PhD, chief research officer of Akay Bioactives, in a press release. “Immufen stands out for its effectiveness and its positive impact on participants' overall well-being."

Reference

1. M.K.; Aryan, M.K.; Pranhakaran, P.; Mulaki, J.N.; S.D.S.; IM, K.; Panicker, S.P. Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study. Front. Allergy. 2024, 5. DOI: 10.3389/falgy.2024.1390813